Canigen DHP

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Canine adenovirus, Canine distemper virus, Canine parvovirus

Available from:

Intervet International BV

ATC code:

QI07AD02

INN (International Name):

Canine adenovirus, Canine distemper virus, Canine parvovirus

Pharmaceutical form:

Lyophilisate for suspension for injection

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Live Viral Vaccine

Authorization status:

Authorized

Authorization date:

2006-04-21

Summary of Product characteristics

Revised: October 2015
AN: 00636/2015
SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE VETERINARY MEDICINAL PRODUCT
Canigen DHP
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single dose of the vaccine vial contains:
_Active ingredients:_
Canine distemper virus, strain Onderstepoort
≥ 10
4.0
TCID
50*
Canine adenovirus 2, strain Manhattan LPV3
≥ 10
4.0
TCID
50*
Canine parvovirus, strain 154
≥ 10
7.0
TCID
50*
*Tissue culture infective dose 50%
For full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Lyophilisate for suspension for injection.
4
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING TARGET SPECIES
For the active immunisation of dogs to reduce clinical signs of
disease caused by canine
distemper virus infection; to prevent clinical signs and viral
excretion caused by canine
parvovirus infection; to reduce clinical signs of canine contagious
hepatitis and viral
excretion due to canine adenovirus 1 infection and to reduce clinical
signs of respiratory
infection and viral excretion caused by adenovirus type 2 infection.
Specific claims:
_Onset of immunity:_
one week
_Duration of immunity:_ three years.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The efficacy of the CDV, CAV2 and CPV components of the vaccine may be
reduced due
to maternal antibody interference. However, the vaccine has been
proved to be of benefit
against virulent challenge in the presence of maternal antibody levels
to CDV, CAV2 and
CPV that are likely to be encountered under field conditions.
Page 1 of 5
Revised: October 2015
AN: 00636/2015
4.5
SPECIAL PRECAUTIONS FOR USE, INCLUDING SPECIAL PRECAUTIONS TO BE TAKEN
BY THE
PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Only healthy dogs should be vaccinated. Dogs should not be exposed to
unnecessary risk
of infection within the first 2 weeks after completion of the
vaccination regimen.
While the canine parvovirus vaccine strain may be shed at very low
levels for up to 8